HealthTree Logo
search more_vert
person Sign In / Create Account
The Importance of Proteasome Inhibitors in Myeloma and Their Evolution in the New Age of Myeloma Therapy with Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute
The Importance of Proteasome Inhibitors in Myeloma and Their Evolution in the New Age of Myeloma Therapy with Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute image
HealthTree Podcast for Multiple Myeloma
event May 13, 2016 / 11:00AM MDT

Event Description

Dr. Jacob Laubach, MD, MPP
Dana Farber Cancer Institute
Interview Date: May 13, 2016

Proteasome inhibitors have been a staple of myeloma therapy since the late 1990s. Because they are so key to the death of myeloma cells, they have continued to be developed and now a variety of options are available. Dr. Jacob Laubach shares more about the history of the PIs in myeloma treatment and why they work so well. He addresses their use in combinations as well as the evolution of their development to hit different portions of the proteasome as well as the development of a new, oral option. Although myeloma patients wish there was a silver bullet cure with the upcoming immunotherapies Dr. Laubach says that this class of drugs is not likely to go away any time soon. He shares how they are now being tested in triple and quadruple combinations to help both newly diagnosed and relapsed/refractory patients extend their outcomes.

multiple myeloma

Thanks to our episode sponsor

Schedule & Agenda

Dr. Jacob Laubach & Jenny Ahlstrom

Speakers & Moderators

The panelist Jacob Laubach, MD, MPP
Jacob Laubach, MD, MPP

Dr. Jacob Laubach, MD is an Assistant Professor in Medicine at Harvard Medical School and the Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute. Dr. Laubach completed his medical degree, residency and fellowship in hematology at Duke University Medical Center in Durham, NC. He joined the Dana Farber Cancer Institute faculty in 2008. Since joining the Dana Farber Cancer Institute faculty in 2008, he has been dedicated to the growth and expansion of the Multiple Myeloma clinical program and to clinical research evaluating new therapeutic agents in Multiple Myeloma. As a clinician, he has a large academic practice focused on the care of patients with plasma cell disorders. In addition, Dr. Laubach played a lead role in the formation of a multi-disciplinary Amyloidosis program at DFCI and Brigham & Women’s Hospital and serving as associate director before being succeeded by Dr. Giada Bianchi in 2018. As a clinical investigator, his research has focused primarily on the development of new therapeutic agents. Dr. Laubach has been involved in the study of histone deacetylase inhibition as a treatment strategy in Multiple Myeloma and in the development of monoclonal antibodies in this disease such as CS-1 (Elotuzumab) and CD38 (Daratumuab). He is currently leading an international phase 2 trial evaluating subcutaneous bortezomib as a component of the standard of care induction regiment lenalidomide, bortezomib, and dexamethasone and was a lead investigator in the recently published GRIFFIN trial evaluating the combination of daratumumab plus RVD. He has also been involved in efforts through the International Myeloma Working Group to update guidelines on management of relapsed and refractory myeloma. Dr. Laubach’s clinical practice has provided frequent opportunities for teaching and mentoring students at Harvard Medical School, Residents at Brigham & Women’s Hospital, and Fellows in the Dana-Farber/Partners CancerCare Hematology/Oncology Fellowship Program.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube